Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
Status:
Recruiting
Trial end date:
2031-12-01
Target enrollment:
Participant gender:
Summary
The hypothesis for this study is that a preparative regimen that maximizes host
immunosuppression without myeloablation will be well tolerated and sufficient for engraftment
of donor hematopoietic cells. It is also to determine major toxicities from these
conditioning regimens, within the first 100 days after transplantation.